Free tool
FAERS Monitor: Stimufend
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761173 or its brand name (Stimufend, Pegfilgrastim-Fpgk). Reports on generic versions are filed under their own applications.
Reports
1
Serious
1
100% of reports
Hospitalization
1
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- anaemia1
- bacterial infection1
- diarrhoea1
- dyspnoea1
- lactic acidosis1
- nausea1
- neutropenia1
- septic shock1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,158 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bacterial infection | 1 | 1127.6 | 1111.5 | 281 |
| lactic acidosis | 1 | 649.4 | 642.4 | 162 |
| septic shock | 1 | 483.5 | 478.9 | 120 |
| neutropenia | 1 | 154.7 | 153.9 | 38 |
| anaemia | 1 | 110.3 | 109.8 | 27 |
| dyspnoea | 1 | 37.2 | 37.1 | 9 |
| diarrhoea | 1 | 32.6 | 32.5 | 7 |
| nausea | 1 | 26.6 | 26.5 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.